COST-EFFECTIVENESS OF USING DETEMIR IN TYPE 2 DIABETES WITH THE RISK OF CARDIOVASCULAR EVENTS AND DEATH

被引：0
|
作者：
Romero, M. [1 ]
Chavez, D. [1 ]
Karpf, E. [1 ]
Alvis, N. [2 ]
机构：
[1] Fdn Salutia, Bogota, Colombia
[2] Univ Cartagena, Cartagena De Indias, Bolivar, Colombia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1591
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A547 / A547
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF INSULIN DETEMIR IN PEOPLE WITH TYPE 2 DIABETES IN ROMANIA
    Ionescu-Targoviste, C.
    Wrona, W.
    Schubert, A.
    Niewada, M.
    Czech, M.
    VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [2] Assessing the influence of modelling subsequent cardiovascular events into a type 2 diabetes cost-effectiveness model
    McEwan, P. H.
    Evans, M.
    Bergenheim, K.
    DIABETOLOGIA, 2010, 53
  • [3] Cost-Effectiveness of Atorvastatin in the Primary Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes in Canada
    Khoury, Hanane
    Wagner, Monika
    Merikle, Elizabeth
    Johnson, Scott J.
    Roberts, Craig
    CANADIAN JOURNAL OF DIABETES, 2009, 33 (04) : 363 - 374
  • [4] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
    Pawlik, D.
    Wojcik, R.
    Zawodnik, A.
    Kaczor, M. P.
    VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
  • [5] An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes
    Home, Philip
    Baik, Sei Hyun
    Gonzalez Galvez, Guillermo
    Malek, Rachid
    Nikolajsen, Annie
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 230 - 240
  • [6] Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
    Jiang, Minghuan
    Li, Pengchao
    You, Joyce Hoi-sze
    Zheng, Xinglong
    Deng, Jizhao
    Zhao, Mingyue
    Feng, Liuxin
    Fang, Yu
    PLOS ONE, 2019, 14 (12):
  • [7] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsapas, Apostolos
    Kourlaba, Georgia
    Papageorgiou, Giannis
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 417 - 426
  • [8] COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE
    Gourzoulidis, G.
    Tzanetakos, C.
    Ioannidis, I.
    Tsapas, A.
    Kourlaba, G.
    Papageorgiou, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
  • [9] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Apostolos Tsapas
    Georgia Kourlaba
    Giannis Papageorgiou
    Nikos Maniadakis
    Clinical Drug Investigation, 2018, 38 : 417 - 426
  • [10] Cost-effectiveness of treatment of type 2 diabetes
    Eastman, RC
    DIABETES CARE, 1998, 21 (03) : 464 - 465
12345